ArticleViruses2023
Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico.
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 8 citations in OpenAlex.
- [Effectiveness of donor selection in a blood bank].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- [Screening of Hepatitis C virus in blood donors over 11 years].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Occult HBV among anti-HBc-reactive blood donors in Colombia: low HBsAg prevalence, genotype F3, and small-S variation relevant to HBsAg detectability.Scientific reports · 2026Article
- Sociodemographic and Lifestyle Determinants of HIF-1α Response to Blood Donation and Hematopoietic Factors: Epidemiological and Public Health Perspectives from Voluntary Donors.Epidemiologia (Basel, Switzerland) · 2026Article
- Review
- Preliminary survey of dengue, Zika and chikungunya viruses by nucleic acid test in blood donors in Shenzhen, China.Frontiers in public health · 2025Article
- Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico.Viruses · 2024Article
- Plasma Photoinactivation of Bacterial Isolated from Blood Donors Skin: Potential of Security Barrier in Transfusional Therapy.Pathogens (Basel, Switzerland) · 2024Article
- An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies.Microorganisms · 2024Review
- [Seroprevalence and risk factor for hepatitis C in Nogales, Sonora].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Hepatitis B Virus Genotype H: Epidemiological, Molecular, and Clinical Characteristics in Mexico.Viruses · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV) can be transmitted by blood transfusion. Most transmission occurs during the acute viremic phase (AVP), before antibody development. To reduce transmission risk, individual donor nucleic acid testing (ID-NAT) is used. In Puebla, Mexico, serological tests and ID-NAT have been applied to screen blood donors and detect individuals in AVP. In the present study, 106,125 blood donors' data in two periods (2012-2015 and 2017-2019) were analyzed. The residual risk (RR) values were calculated considering ID-NAT results. The RR for HIV was 14 in 1 million donations or 1 in 71,428, the RR for HVC was 6.8 in 1 million donations or 1 in 147,058 and, for HBV, it was 156 in 1 million donations, or 1 in 6410. Previously, it was predicted that the transmission RR of these viruses would be reduced in Mexico through better screening with NAT. The use of ID-NAT has, indeed, increased the safety of blood reserves for HIV and HCV. However, more research is needed to determine why the residual risk of HBV did not decrease as much over the study period. ID-NAT is an important complementary tool for blood donor screening that should be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.